庚酸炔诺酮(Norethisterone Enanthate) - 药物靶点：PR_在研适应症：不孕，子宫出血_专利_临床

概要

基本信息

药物类型

小分子化药

别名

NORETHISTERONE ENANTHAS、Norethisterone oenanthate

+ [4]

靶点

PR

作用机制

PR激动剂(孕激素受体激动剂)

治疗领域

泌尿生殖系统疾病

在研适应症

不孕子宫出血

非在研适应症-

原研机构

浙江仙琚制药股份有限公司

在研机构

浙江仙琚制药股份有限公司

非在研机构

Bayer AG

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

结构

分子式C27H38O3

InChIKeyAPTGJECXMIKIET-WOSSHHRXSA-N

CAS号3836-23-5

关联

11

项与庚酸炔诺酮相关的临床试验

NCT05362019 / Not yet recruitingN/AIIT

Effects of One-to-one Service on the Continuation and Satisfaction of Combined Injectable Contraceptive Use.

This study aims to explore the impact of a mobile based one-to-one service model on improving the continuation and satisfaction of combined injectable contraceptive use, and improve the utilization and acceptability of efficient and long-term contraceptive methods.

开始日期2022-05-01

申办/合作机构-

SLCTR/2017/037 / Suspended临床2期

Efficacy of the combination of oral tranexamic acid with oral norethisterone versus oral tranexamic acid alone in treatment of bleeding per vagina during dengue infection - A single blinded,randomized controlled study

开始日期2017-12-01

申办/合作机构

National Science Foundation

NCT02905890 / Completed临床4期IIT

Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda

The proposed study, Hormonal Contraception & BV (HCBV), will investigate the effect of NET-EN and DMPA on recurrent BV, vaginal microbiota and inflammatory markers among women at high risk for HIV in Kampala, Uganda. The hypothesis is that NET-EN will show a similar beneficial effect on recurrent BV and vaginal microbiota as DMPA, without inducing signs of mucosal inflammation.

开始日期2017-10-02

申办/合作机构

London School of Hygiene & Tropical Medicine

[+2]

100 项与庚酸炔诺酮相关的临床结果

登录后查看更多信息

100 项与庚酸炔诺酮相关的转化医学

登录后查看更多信息

100 项与庚酸炔诺酮相关的专利（医药）

登录后查看更多信息

300

项与庚酸炔诺酮相关的文献（医药）

2023-11-01·American journal of reproductive immunology (New York, N.Y. : 1989)

Contraceptive effects on the cervicovaginal microbiome: Recent evidence including randomized trials.

Review

作者: Heffron, Renee ; Jaspan, Heather B ; Balle, Christina ; Happel, Anna-Ursula

BACKGROUNDUntil recently, most data regarding the effects of non-barrier contraceptives on the mucosal microbiome have derived from observational studies, which are potentially biased due to behavioral confounders that may mask their true biological effects.METHOD OF STUDYThis narrative review summarises recent evidence of the effect of contraceptives on the cervicovaginal microbiome, emphasising data obtained through randomized trials.RESULTSGood quality data describe that initiation of long-acting progestin-only contraceptives, including levonorgestrel (LNG)-implant and the injectables depot-medroxyprogesterone acetate (DMPA-IM) and norethisterone enanthate (NET-EN) do not alter the mucosal microbial environment. Likewise, no strong evidence exists that the use of oral contraceptive pills (OCPs) is associated with alterations of the vaginal microbiome or increased risk of bacterial sexually transmitted infections (STIs). Limited data on the effect of intravaginal rings (IVRs) on the mucosal environment exist and show conflicting effects on the vaginal microbiota. Copper intrauterine device (Cu-IUD) initiation has been associated with bacterial vaginosis (BV) acquisition, including in a randomized trial. LNG-IUDs may have similar affects but need to be evaluated further.CONCLUSIONDifferent synthetic hormones have divergent effects on the microbiome and therefore novel hormonal methods need to be rigorously evaluated. Furthermore, the addition of antiretrovirals into multipurpose technologies may alter the effects of the hormonal component. There is thus a critical need to improve our understanding of the biological effects of contraceptive hormones and delivery methods with different pharmacokinetic and chemical properties on the mucosal microbiome in rigorous trials, to inform the development of novel contraceptives and improve individual family planning guidance.

2021-08-01·American Journal of Reproductive Immunology3区 · 医学

Genital and systemic immune effects of the injectable, contraceptive norethisterone enanthate (NET‐EN), in South African women

3区 · 医学

Article

作者: Mchunu, Nobuhle ; Molatlhegi, Refilwe P. ; Zondi, Mthobisi M. ; Ngcapu, Sinaye ; Samsunder, Natasha ; Govender, Katya ; Leslie, Alasdair ; Ngcobo, Samkelisiwe ; Liebenberg, Lenine J. P. ; Adamson, John H. ; Sivro, Aida ; Mabhula, Amanda ; Karim, Quarraisha Abdool ; Passmore, Jo‐Ann S. ; McKinnon, Lyle R. ; Karim, Salim S. Abdool

AbstractProblemInjectable hormonal contraceptives (IHC) have been associated with altered mucosal and systemic milieu which might increase HIV risk, but most studies have focused on DMPA and not NET‐EN, despite the growing popularity and lower HIV risk associated with the latter in observational studies.Method of studyWe used high‐performance liquid chromatography in combination with tandem triple quadrupole mass spectrometry (HPLC‐LC‐MS/MS) to measure steroid hormones in plasma samples of CAPRISA004 study participants. Concentrations of 48 cytokines were measured in the cervicovaginal lavage (CVL) and plasma, and their expression was compared between participants with detectable NET‐EN (n = 201) versus non‐detectable IHC (n = 90). Each log10 cytokine concentration was tested as an outcome in linear‐mixed models, with NET‐EN detection as the main explanatory variable. Multivariable models were adjusted for potential confounders.ResultsIn bivariate analysis, detectable NET‐EN was associated with reduced cervicovaginal M‐CSF (P = 0.008), GM‐CSF (P = 0.025) and G‐CSF (P = 0.039), and elevated levels MIF (P = 0.008), IL‐18 (P = 0.011), RANTES (P = 0.005) and IL‐1Rα (P < 0.001). Lower G‐CSF (P = 0.011) and elevated IL‐1Rα (P = 0.008) remained significant in adjusted models. Multivariable analyses of plasma samples obtained from NET‐EN‐detectable women showed a significant increase in IP‐10 (P = 0.026) and reductions in TNF‐β (P = 0.037), RANTES (P = 0.009), and M‐CSF (P < 0.001). While similar growth factor reduction in CVL was noted for both DMPA and NET‐EN, similar trends were not observed for endogenous progesterone.ConclusionsDetectable NET‐EN was associated with reduced growth factors in the plasma and genital tract; particularly G‐CSF and M‐CSF. Our results suggest that while NET‐EN is not inflammatory, it may have important immunological effects.

2021-07-01·American Journal of Reproductive Immunology3区 · 医学

Effect of injectable progestin‐only contraceptives, depot medroxyprogesterone acetate and norethisterone enanthate, on cytokine production during T‐cell activation

3区 · 医学

Article

作者: Mhlanga, Felix ; Mbizvo, Mike ; Stoner, Kevin A. ; Achilles, Sharon L. ; Meyn, Leslie A. ; Chirenje, Zvavahera M. ; Maramba, Aaron ; Hillier, Sharon L. ; Matubu, Allen T.

AbstractProblemThere is paucity of human data about the effects of depot medroxyprogesterone (DMPA) and norethisterone enanthate (Net‐En) use on systemic immune function, which may have implications for reproductive tract infection susceptibility and transmissibility. We sought to evaluate the impact of injectable contraceptive use on T‐cell responsiveness using T cells exposed in vivo and tested ex vivo.MethodsPeripheral blood mononuclear cells were obtained from healthy, HIV‐negative women after 30, 90 and 180 days of DMPA, norethisterone enanthate (Net‐En) or copper intrauterine device (Cu‐IUD) contraceptive use. Cells were stimulated ex vivo with phorbol myristate acetate and ionomycin, stained and analysed using flow cytometry. Mixed‐effects linear models were used to evaluate change in proportions of T cells producing IFN‐γ, TNF‐α, IL‐4 and IL‐13.ResultsCompared with baseline, decreased proportions of IFN‐γ–producing CD4+ and CD8+ T cells (p = .003, p = .006, respectively) and TNF‐α–producing CD4+ and CD8+ T cells (p = .039, p = .034, respectively) were observed after 180 days of DMPA use. Decreased IL‐4–producing CD4+ and CD8+ T cells (p = .045 and p = .024, respectively) were noted after 180 days of Net‐En use. Decreased IL‐4–producing CD4+ T cells were observed after 30 days (p = .035) and not after 180 days of DMPA use (p = .49). There were no changes in proportion of T cells producing IL‐13 in DMPA users, nor any changes in IFN‐γ, TNF‐α and IL‐13 in Net‐En and Cu‐IUD users.ConclusionIn vivo exposure of CD4+ and CD8+ T cells to typical pharmacologic concentrations of DMPA does not cause broad suppression to stimuli; however, depletion of specific cytokine‐producing T cells may occur after prolonged DMPA use.

100 项与庚酸炔诺酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	庚酸炔诺酮	G03AC01 G03DC02	DB14678

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
不孕	中国	浙江仙琚制药股份有限公司	-
子宫出血	中国	浙江仙琚制药股份有限公司	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MDP 301 (IAS2018)	N/A	单纯疱疹	621	Depo-medroxyprogesterone acetate (DMPA)	積壓築鹹觸鏇構憲鬱範(鹽糧衊艱觸窪鹹積鏇鏇) = 鏇遞憲鏇繭醖壓壓網願網襯鏇顧鹹選膚淵製積 (齋鏇鏇鏇夢觸築鬱憲鏇 )	-	2018-01-01
				Norethisterone enanthate (Net-EN)	積壓築鹹觸鏇構憲鬱範(鹽糧衊艱觸窪鹹積鏇鏇) = 壓膚餘鑰繭顧齋膚壓顧網襯鏇顧鹹選膚淵製積 (齋鏇鏇鏇夢觸築鬱憲鏇 )
IAS2006	N/A	HIV感染	4,200	Combined oral contraceptives (COC)	蓋醖齋餘夢壓夢獵簾製(窪願範餘襯艱窪觸艱餘) = 鏇鏇築憲鏇齋構構夢願窪艱顧艱鏇鬱築鬱繭築 (窪廠襯壓獵獵襯鹹壓積, 0.16 ~ 2.66)	-	2006-01-01
				Norethindrone enanthate (NET-EN)	蓋醖齋餘夢壓夢獵簾製(窪願範餘襯艱窪觸艱餘) = 夢壓選鏇積餘醖顧鏇築窪艱顧艱鏇鬱築鬱繭築 (窪廠襯壓獵獵襯鹹壓積, 0.31 ~ 2.02)
Pubmed \| AIDS	N/A	-	-	DMPA-IM	(築築顧膚簾餘製鹹膚襯) = 蓋夢襯鬱築壓壓製窪醖觸網鹽觸廠醖衊鹹簾糧 (遞襯築製遞衊蓋齋餘鹽 )	-	2019-08-01
				norethisterone enanthate	(築築顧膚簾餘製鹹膚襯) = 積繭餘簾蓋製願廠醖鬱觸網鹽觸廠醖衊鹹簾糧 (遞襯築製遞衊蓋齋餘鹽 )
IAS2016	N/A	HIV感染	232	Depot medroxyprogesterone acetate (DMPA)	襯餘鹽壓醖選醖壓鹽遞(網願襯膚築艱願襯憲艱): Unadjusted HR = 0.67 (95% CI, 0.24 ~ 1.85); Adjusted HR = 0.71 (95% CI, 0.26 ~ 1.97) 更多	-	2016-01-01
				Norethisterone enanthate (NET-EN)